ANPM (Tunisia)

DPM (the Direction de la Pharmacie et du Médicament, transitioning to ANPM — Agence Nationale du Médicament) is the Republic of Tunisia's national regulatory authority responsible for the regulation of human medicines + biologicals + vaccines + medical devices + IVDs + pharmacy practice + cosmetics + drugs of abuse + pharmaceutical-industry oversight. DPM has historically operated as a Directorate within the Ministry of Health (Ministère de la Santé) — institutionally similar to Morocco DMP + Peru DIGEMID + France ANSM's pre-1993 status. Tunisia is progressively transitioning toward an autonomous-agency model (the ANPM — Agence Nationale du Médicament) consolidating medicines + biologicals + devices + cosmetics regulation, expanding fee-retention + scientific autonomy, + aligning institutional status with peer Maghreb regulators (Morocco DMP, Algeria ANPP) + the broader autonomous-agency trend across African + Arab + Latin American regulators.

DPM/ANPM traces its origins to Law 73-55 of 3 August 1973 organising the pharmaceutical sector (one of the foundational post-independence Tunisian pharmaceutical regulations, building on the 1957 health-system reforms) + has been progressively reformed through Law 85-91 of 22 November 1985 (controlled substances + narcotics + psychotropics framework), Law 99-71 of 26 July 1999 (clinical trials + pharmacovigilance framework — the first comprehensive Tunisian CT + PV legislation), Law 2009-43 of 30 June 2009 (medical devices framework), Law 2016-22 (cosmetics framework substantively aligned with EU Cosmetics Regulation), + a substantial body of Ministerial Decrees (Décrets) + DPM Arrêtés + Circulaires. Tunisia has substantial domestic pharmaceutical manufacturing capacity with ~40 manufacturers including Saïph (Société Arabe des Industries Pharmaceutiques), Adwya, Médis, Opalia, Unimed, + several joint-venture facilities; Tunisia is a substantial generic-medicines exporter to sub-Saharan Africa + the Maghreb + the broader Arab World.

DPM/ANPM's organisational structure includes:

• Directeur de la Pharmacie et du Médicament (transitioning to Directeur Général de l'ANPM) — chief executive appointed by the Minister of Health; serves at Ministerial discretion.
• Sous-Direction des Autorisations de Mise sur le Marché (AMM) — drug + biological + vaccine + biosimilar + generic-medicine registration via Marketing Authorisation procedure.
• Sous-Direction de l'Inspection Pharmaceutique — Tunisian + foreign manufacturer + distributor + pharmacy GMP/GDP/GPP inspections.
• Sous-Direction des Dispositifs Médicaux + Cosmétiques — medical-device + IVD + cosmetic registration + post-market matériovigilance + cosmétovigilance per Law 2009-43 + Law 2016-22.
• Sous-Direction de la Pharmacovigilance — Centre National de Pharmacovigilance (CNPV Tunis) coordination + adverse-event surveillance + WHO PIDM coordination.
• Sous-Direction de la Pharmacie Hospitalière + Officinale — pharmacy practice + pharmacy premises licensing + pharmaceutical-establishment authorisation.
• Sous-Direction de l'Économie Pharmaceutique — pharmaceutical-price regulation + reimbursement coordination with CNAM (Caisse Nationale d'Assurance Maladie).
• Sous-Direction de la Coopération + Affaires Internationales — international cooperation + WHO + AMRH + AMA + EU + UMA + Arab League + UfM coordination.
• LNCM (Laboratoire National de Contrôle des Médicaments, Tunis) — central pharmaceutical QC laboratory; ISO/IEC 17025 accredited + pursuing WHO PQ-Lab designation.
• CNPV (Centre National de Pharmacovigilance, Tunis) — national pharmacovigilance + matériovigilance + cosmétovigilance + réactovigilance + toxicovigilance centre operating under DPM/ANPM coordination.
• Commission Nationale Consultative d'AMM (CNCAMM) — advisory commission with academic + medical + pharmaceutical industry + civil society representation issuing scientific opinions on AMM applications.
• Pharmacie Centrale de Tunisie (PCT) — central pharmaceutical procurement + distribution organisation supporting public-sector medicines supply (separate from DPM/ANPM regulatory function).
• Network of regional pharmacy inspectors coordinated through Direction Régionale de la Santé in each of Tunisia's 24 governorates.

DPM/ANPM is distinct from + complementary to: the Ministry of Health broader Directorates (Direction des Soins de Santé de Base, Direction des Hôpitaux, Direction de la Médecine Préventive); the Conseil National de l'Ordre des Pharmaciens (Order of Pharmacists, pharmacist professional body); the ANCSEP (Agence Nationale de Contrôle Sanitaire et Environnemental des Produits, food safety + water + environmental sanitary control); the DGSV (Direction Générale des Services Vétérinaires, veterinary medicines + animal-origin foods, sitting under Ministry of Agriculture); the INNTA (Institut National de Nutrition et de Technologie Alimentaire); the IPT (Institut Pasteur de Tunis, biological research + vaccine production + WHO Collaborating Centre); the Pharmacie Centrale de Tunisie (PCT, public-sector pharmaceutical procurement + distribution); + the CAPHARMA (Chambre Syndicale Nationale des Producteurs Pharmaceutiques, Tunisian pharmaceutical industry association). DPM/ANPM's institutional environment is characterised by substantial Tunisian domestic pharmaceutical manufacturing + substantial generic-medicines export capacity + Francophone + EU + Mediterranean + Arab regulatory tradition alignment.

Legal foundations are Law 73-55 of 3 August 1973 (organisation of the pharmaceutical sector); Law 85-91 of 22 November 1985 (controlled substances + narcotics + psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988); Law 99-71 of 26 July 1999 (clinical trials + pharmacovigilance framework); Law 2009-43 of 30 June 2009 (medical devices framework); Law 2016-22 (cosmetics framework substantively aligned with EU Cosmetics Regulation); Decree 90-1400 + successor decrees (pharmacy practice + pharmacy premises licensing + pharmaceutical-establishment authorisation); Decree 90-1401 + successor decrees (AMM procedures + variations + renewal); + a substantial body of DPM Arrêtés + Circulaires + Notes Techniques. Tunisian pharmaceutical regulation operates substantively in French (administrative + scientific language) with Arabic (official Constitution language) labelling requirements.

DPM/ANPM is a WHO Listed Authority candidate + an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority + an active AMRH (African Medicines Regulatory Harmonisation) co-Reference Authority + an AMA (African Medicines Agency) Technical Committee participant + a Union for the Mediterranean (UfM) regulatory cooperation partner + an active League of Arab States Council of Arab Ministers of Health pharmaceutical-harmonisation participant + a founding Arab Maghreb Union (UMA) pharmaceutical cooperation partner. DPM/ANPM holds substantial cooperation arrangements with ANSM France (historic Francophone alignment) + AIFA Italy + AEMPS Spain + PEI Germany + EMA + Morocco DMP + Algeria ANPP + Libya NRA + Mauritania DPL + Egyptian EDA + Saudi SFDA + Jordanian JFDA + AMA-positioned for full Continental African coordination.

Tunisian pharmaceutical regulation operates under a layered framework of Laws + Decrees + DPM/ANPM Arrêtés + Notes Techniques:

• Law 73-55 of 3 August 1973 — organisation of the pharmaceutical sector; foundational text establishing DPM authority + framework.
• Law 85-91 of 22 November 1985 — controlled substances + narcotics + psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988; coordinates with INCB.
• Law 99-71 of 26 July 1999 — clinical trials + pharmacovigilance framework; first comprehensive Tunisian CT + PV legislation.
• Law 2009-43 of 30 June 2009 — medical devices framework with Class I-III risk-based classification substantively aligned with EU MDR predecessor + GHTF/IMDRF.
• Law 2016-22 — Tunisian cosmetics framework substantively aligned with EU Cosmetics Regulation including INCI ingredient listing + safety substantiation + cosmétovigilance.
• Decree 90-1400 + successor decrees — pharmacy practice + pharmacy premises licensing + pharmaceutical-establishment authorisation.
• Decree 90-1401 + successor decrees — AMM (Autorisation de Mise sur le Marché) procedures + variations + 5-year renewal framework.
• DPM/ANPM Bonnes Pratiques de Fabrication (BPF) — Tunisian GMP framework substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2.
• DPM/ANPM Bonnes Pratiques de Distribution (BPD) — Tunisian GDP framework substantively aligned with WHO + EU GDP.
• DPM/ANPM Bonnes Pratiques Cliniques (BPC) — Tunisian GCP framework substantively aligned with ICH E6(R2).
• DPM/ANPM Bonnes Pratiques de Pharmacovigilance (BPPv) — Tunisian PV framework substantively aligned with ICH E2 + EU GVP.
• Pharmacopée Tunisienne — Tunisian Pharmacopoeia; recognises European Pharmacopoeia + USP + BP + Pharmacopée Tunisienne monographs.
• AMM Variations + 5-year Renewal Arrêtés — variations classification + procedures + mandatory 5-year AMM renewal framework.
• ANPM Transition Framework — progressive legislative + regulatory framework consolidating DPM into autonomous ANPM agency with expanded scientific autonomy + fee-retention.

LNCM Tunis (the Laboratoire National de Contrôle des Médicaments) is DPM/ANPM's central pharmaceutical quality-control laboratory in Tunis + is ISO/IEC 17025 accredited (TUNAC — Conseil National d'Accréditation) + pursuing WHO Prequalification of Quality Control Laboratories (WHO PQ-Lab) designation. WHO PQ-Lab designation would position LNCM Tunis alongside South Africa NCL + Ethiopia NFBMQCL + Tanzania NCQAL + Morocco LNCM + Egypt EDA NODCAR as one of the few WHO-prequalified pharmaceutical QC laboratories in Africa + the Mediterranean basin.

• ISO/IEC 17025 Accreditation — LNCM Tunis is ISO/IEC 17025 accredited (TUNAC) across multiple testing scopes including pharmaceutical chemical + microbiological + biological testing.
• WHO PQ-Lab Candidate — LNCM Tunis is pursuing WHO PQ-Lab designation; would provide Tunisia with WHO-recognised pharmaceutical QC capacity supporting WHO PQ + DPM/ANPM regulatory testing + Global Fund + Gavi + UNICEF procurement support.
• AMRH + AFRO Regional Reference Laboratory Candidate — LNCM Tunis positioned for AMRH-coordinated regional reference-laboratory functions for sub-Saharan African + Francophone Africa medicines QC capacity.
• Institut Pasteur de Tunis (IPT) — Tunis-based WHO Collaborating Centre + biological research + vaccine production; coordinates with LNCM Tunis for vaccine + biological testing + WHO PIDM contributions.
• Vaccine lot release — LNCM Tunis + IPT conduct vaccine lot-release testing for DPM/ANPM + Tunisian PEV + selected African vaccine programmes.
• Pharmaceutical pre-registration + post-market testing — LNCM Tunis conducts pre-registration quality testing + post-market surveillance + targeted enforcement testing for DPM/ANPM.
• Counterfeit-medicine forensics — LNCM Tunis provides forensic analytical support for DPM/ANPM + Direction Générale de la Douane investigations + WHO Global Surveillance & Monitoring System contributions.
• Capacity-building — LNCM Tunis hosts AMRH + AMA + UMA + Union for the Mediterranean + Council of Arab Ministers of Health capacity-building programmes + training for African + Mediterranean + Arab pharmaceutical analysts.
• GMP Inspectorate support — LNCM Tunis provides scientific + technical support for DPM/ANPM GMP inspections of Tunisian + foreign manufacturing facilities.
• Pharmacopée Tunisienne development — LNCM Tunis contributes to Pharmacopée Tunisienne monograph development alongside European + International Pharmacopoeia harmonisation.

DPM/ANPM medical-device + IVD regulation operates under Law 2009-43 of 30 June 2009 with Class I-III risk-based framework substantively aligned with EU MDR predecessor (Directive 93/42/EEC era at adoption, progressively updated) + GHTF/IMDRF + AMRH-MDH. Foreign manufacturers must appoint a Tunisian Authorised Representative (Représentant Autorisé).

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR predecessor + GHTF/IMDRF + AMRH-MDH; IVDs classified under separate Tunisian IVD framework.
• Représentant Autorisé Tunisien — Tunisia-resident legal entity required for foreign manufacturers; bears post-market matériovigilance responsibility + DPM/ANPM regulatory interface.
• ISO 13485:2016 — recognised by DPM/ANPM as QMS evidence framework; Tunisian-specific overlay required including Tunisian quality records + Représentant Autorisé QMS interface.
• Reliance pathways — DPM/ANPM accepts CE Mark + FDA 510(k) + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; CE Mark particularly central given francophone + EU regulatory tradition.
• AMRH Medical Devices Harmonisation — DPM/ANPM participates in AMRH-MDH work-streams; reliance + harmonised technical-file requirements progressively expanding across African Member States.
• Union for the Mediterranean Medical-Device Cooperation — DPM/ANPM participates in UfM medical-device regulatory cooperation alongside EU Mediterranean Member States + Mediterranean Partner Countries.
• Post-market matériovigilance — DPM/ANPM operates medical-device adverse-event reporting through the Tunisian Matériovigilance System coordinated by CNPV; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• Cosmetic Notification — cosmetics under Law 2016-22 require Cosmetic Notification + French + Arabic labelling; INCI-aligned ingredient listing + safety substantiation + cosmétovigilance reporting; substantively EU-aligned framework.
• Tunisian UDI — DPM/ANPM is progressively implementing UDI requirements substantively aligned with FDA UDI + EU EUDAMED UDI; Tunisian-specific overlay applies.
• Importation Permit — DPM/ANPM Importation Permit required in addition to product registration for foreign-manufactured devices entering Tunisia; coordination with Direction Générale de la Douane.

DPM/ANPM operates the Tunisian Pharmacovigilance Programme through coordination with CNPV (Centre National de Pharmacovigilance, Tunis). Tunisia is a long-standing WHO Programme for International Drug Monitoring (PIDM) member (since 1993) + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre (UMC). CNPV operates Tunisia's integrated pharmacovigilance + matériovigilance + cosmétovigilance + réactovigilance + toxicovigilance centre — an integrated model providing efficient resource use across vigilance functions.

• Centre National de Pharmacovigilance (CNPV, Tunis) — integrated pharmacovigilance + matériovigilance + cosmétovigilance + réactovigilance + toxicovigilance centre operating under DPM/ANPM coordination.
• WHO PIDM Long-standing Member — Tunisia is a WHO PIDM member since 1993 + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
• Réseau Tunisien de Pharmacovigilance — coordinated national pharmacovigilance network with effector centres in major university hospitals (CHU Charles Nicolle Tunis, CHU La Rabta Tunis, CHU Sahloul Sousse, CHU Hédi Chaker Sfax, CHU Farhat Hached Sousse) + Direction Régionale de la Santé + Marketing Authorisation Holders.
• Online ADR Reporting — DPM/ANPM/CNPV operates online ADR reporting via the CNPV portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — DPM/ANPM accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); DPM/ANPM-specific submission timeline.
• Risk Management Plans (RMP) — DPM/ANPM requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — DPM/ANPM/CNPV operates targeted active-surveillance programmes including for HIV antiretrovirals + tuberculosis + COVID-19 vaccines + biologicals + sentinel-site hospital surveillance through major Tunisian CHUs.
• Manifestations Postvaccinales Indésirables (MAPI) — Tunisian vaccine adverse-event surveillance aligned with WHO methodology; central to PEV + COVID-19 vaccine safety monitoring.
• Matériovigilance + Cosmétovigilance + Réactovigilance — DPM/ANPM/CNPV operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics + réactovigilance for IVDs.

• WHO Listed Authority Candidate — DPM/ANPM is a WHO Listed Authority candidate based on active WHO PQ CRP participation + LNCM Tunis WHO PQ-Lab trajectory + AMRH co-Reference Authority designation.
• WHO PQ CRP Participating Authority — DPM/ANPM is an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority.
• WHO PQ-Lab Candidate — LNCM Tunis is pursuing WHO PQ-Lab designation.
• AMRH co-Reference Authority — DPM/ANPM is an active AMRH (African Medicines Regulatory Harmonisation) co-Reference Authority alongside SAHPRA + Ghana FDA + Kenya PPB + Tanzania TMDA + Uganda NDA + Rwanda FDA + Nigeria NAFDAC + Egyptian EDA + Ethiopia EFDA + Morocco DMP + Algeria ANPP.
• AMA Technical Committee Participant — DPM/ANPM participates in African Medicines Agency (AMA) Technical Committees under AU Decision Assembly/AU/Dec.857(XXXVII) + Kigali HQ coordination.
• Arab Maghreb Union (UMA) Founding Partner — DPM/ANPM is a founding UMA pharmaceutical cooperation partner alongside Morocco DMP + Algeria ANPP + Libya NRA + Mauritania DPL; though UMA broadly dormant since 1994 closure of Morocco-Algeria border, pharmaceutical-cooperation channels remain through bilateral coordination.
• Union for the Mediterranean (UfM) Partner — DPM/ANPM participates in UfM regulatory cooperation alongside EU Mediterranean Member States (France, Spain, Italy, Portugal, Greece, Cyprus, Malta) + Mediterranean Partner Countries (Morocco, Algeria, Egypt, Israel, Jordan, Lebanon, Palestine, Turkey).
• League of Arab States Council of Arab Ministers of Health — active pharmaceutical-harmonisation participant alongside Egyptian EDA + Saudi SFDA + Morocco DMP + Algerian ANPP + Jordanian JFDA + UAE MoHAP + Lebanese MoH + Kuwait MoH + Bahrain NHRA + others.
• EMA Cooperation — DPM/ANPM holds informal cooperation with EMA covering information exchange + reliance + capacity-building; reflects Tunisia's francophone + EU-aligned regulatory tradition.
• ANSM France Bilateral — DPM/ANPM holds substantial bilateral cooperation with ANSM France reflecting historic Franco-Tunisian ties + francophone regulatory alignment; ANSM France provides training + scientific cooperation + expert exchanges.
• AIFA Italy + AEMPS Spain + PEI Germany Bilateral — DPM/ANPM holds bilateral cooperation with AIFA Italy + AEMPS Spain + PEI Germany reflecting Mediterranean + EU regulatory cooperation.
• ICH Observer Candidate — DPM/ANPM is positioned for ICH Observer status; ICH guidelines extensively implemented in Tunisian regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• IMDRF Affiliate Candidate — DPM/ANPM is positioned for IMDRF Affiliate status + draws on IMDRF guidance for medical-device regulation.
• PIC/S Pre-Accession Pathway — DPM/ANPM is on PIC/S Pre-Accession pathway; BPF framework substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7.
• ICDRA + AVAREF participation — active International Conference of Drug Regulatory Authorities + African Vaccine Regulatory Forum (AVAREF) participant.

• Tunisian Représentant Autorisé not properly designated — application rejected at DPM/ANPM intake or post-approval compliance failure.
• French + Arabic labelling deficiencies — French + Arabic labelling required; many applicants provide insufficient Arabic-language notice patient or use European French rather than Tunisian French terminology.
• BPF gaps — applicants assuming EU GMP / PIC/S GMP compliance is automatically sufficient without addressing Tunisia-specific DPM/ANPM BPF clarifications + Tunisian quality records.
• Tunisian climate-zone stability data missing — Tunisia spans Climate Zone II (Mediterranean coastal Tunis-Bizerte-Sousse-Sfax) + Climate Zone IVa (interior + pre-Saharan southern governorates including Gabès, Médenine, Tataouine, Kebili, Tozeur); many applicants provide insufficient zonal-specific stability data particularly for southern Saharan distribution.
• Bioequivalence centres + biowaiver — DPM/ANPM Biowaiver Guidance provides BCS-based biowaivers + applicants frequently submit BE studies where biowaivers would suffice; alternatively many submit insufficient BE evidence where studies are required.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated DPM/ANPM CRP review (90-day target); under-utilised by many applicants.
• AMRH / AMA reliance not leveraged — AMRH co-Reference Authority + AMA Technical Committee reliance pathways under-utilised; provides substantial acceleration for African-Reference-Authority-assessed products.
• EU / EMA / ANSM France reliance under-utilised — DPM/ANPM operates strong reliance on EMA + ANSM France + AIFA Italy + AEMPS Spain decisions reflecting Tunisia's francophone + Mediterranean alignment; under-utilised by many applicants.
• UMA / Arab League harmonisation not leveraged — UMA pharmaceutical cooperation + Council of Arab Ministers of Health pharmaceutical-harmonisation reliance under-utilised for Maghreb + Arab-Reference-Authority-assessed products (Morocco DMP, Algeria ANPP, Egypt EDA, Saudi SFDA, Jordanian JFDA).
• Vital + Essential Medicines accelerated pathway not leveraged — accelerated AMM for Liste Nationale des Médicaments Essentiels + CNAM-procurement-priority products under-utilised; 90-120 working day target.
• DGSV jurisdictional split — veterinary medicines + animal-origin foods sit with DGSV (Direction Générale des Services Vétérinaires) under Ministry of Agriculture, not DPM/ANPM; avoid filing veterinary applications to DPM/ANPM.
• ANCSEP jurisdictional split — food safety + water + environmental sanitary control sit with ANCSEP (Agence Nationale de Contrôle Sanitaire et Environnemental des Produits), not DPM/ANPM.
• Ministry-Directorate institutional position — DPM's Ministry-of-Health Directorate-level status (transitioning to autonomous ANPM agency) means fee-retention is currently limited + direct Ministerial accountability shapes decision-making; ANPM transition will progressively expand institutional autonomy.
• Variations strategy not planned — variations procedure substantively similar to EU but with Tunisia-specific timelines + fee structure + French/Arabic-language requirements.
• AMM renewal timing missed — 5-year AMM renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Clinical trial CNEM + Law 99-71 steps — Tunisian clinical trials require DPM/ANPM Autorisation d'Essai Clinique + Comité National d'Éthique Médicale (CNEM) approval; sponsors sometimes overlook CNEM recognition + multi-CHU clinical-trial coordination.
• Pharmacovigilance + CNPV gaps — DPM/ANPM BPPv requirements substantively similar to ICH E2 + EU GVP but with Tunisia-specific CNPV integrated vigilance coordination + French + Arabic ICSR.

V5 Ultimate provides the operational infrastructure Tunisian + foreign-supplier sites need for Law 73-55 of 1973 + Law 99-71 of 1999 + Law 2009-43 of 2009 + DPM/ANPM BPF + DPM/ANPM Medical Devices framework + AMRH + AMA + UMA + Union for the Mediterranean + Arab League + WHO PQ CRP + Tunisian Pharmacovigilance Programme readiness.

• DPM/ANPM BPF control framework — PIC/S + EU GMP + ICH Q7-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Tunisia-specific clarifications + Climate Zone II/IVa stability monitoring.
• DPM/ANPM AMM dossier packaging — Tunisian CTD-aligned dossier structure with Tunisia Module 1 specifics + Module 3 stability + French + Arabic notice patient + Représentant Autorisé declarations + Law 73-55 + Law 99-71 framework.
• AMRH / AMA workflow — AMRH co-Reference Authority + AMA Technical Committee packaging for joint assessment + reliance across African Member States.
• WHO PQ CRP workflow — DPM/ANPM-as-CRP-participating-authority packaging with reduced dossier + accelerated DPM/ANPM review (90-day target).
• EU / EMA / ANSM France reliance workflow — Working Arrangement + ANSM France bilateral cooperation packaging reflecting Tunisia's francophone + Mediterranean alignment.
• UMA workflow — Arab Maghreb Union pharmaceutical cooperation packaging alongside Morocco DMP + Algeria ANPP + Libya NRA + Mauritania DPL.
• Union for the Mediterranean workflow — UfM regulatory cooperation packaging alongside EU Mediterranean Member States + Mediterranean Partner Countries.
• Arab League workflow — Council of Arab Ministers of Health pharmaceutical-harmonisation packaging with Egyptian EDA + Saudi SFDA + Morocco DMP + Algerian ANPP + Jordanian JFDA + UAE MoHAP coordination.
• Vital + Essential Medicines accelerated workflow — Liste Nationale des Médicaments Essentiels + CNAM-procurement-priority product packaging with 90-120 working day accelerated review.
• Tunisian Représentant Autorisé workflow — foreign-manufacturer Représentant Autorisé designation + role-management + Tunisia-specific post-market surveillance + DPM/ANPM interface.
• Tunisian clinical-trial workflow — DPM/ANPM Autorisation d'Essai Clinique + CNEM + multi-CHU coordination + Tunisian SUSAR reporting via CNPV.
• DPM/ANPM/CNPV Pharmacovigilance integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + French + Arabic ICSR + Réseau Tunisien de Pharmacovigilance coordination + CNPV portal submission + VigiBase upload + Risk Management Plan packaging + MAPI vaccine adverse-event reporting.
• Matériovigilance + Cosmétovigilance + Réactovigilance workflow — parallel matériovigilance + cosmétovigilance + IVD-vigilance packaging coordinated through CNPV.
• Medical-device + cosmetic + IVD workflow — Law 2009-43 + Law 2016-22 dossier packaging + Class I-III classification + ISO 13485 + Représentant Autorisé + post-market matériovigilance.
• ANPM transition support — progressive ANPM autonomous-agency framework support; V5 surfaces transitional + post-transition regulatory packaging.
• AMRH + AMA + UMA + UfM + Arab League regional bridging — for companies operating across Africa + the Maghreb + the Mediterranean + the Arab World, V5 surfaces DPM/ANPM + Morocco DMP + Algeria ANPP + Egyptian EDA + Saudi SFDA + Jordanian JFDA + UAE MoHAP + SAHPRA + Ghana FDA + Kenya PPB + Tanzania TMDA + Uganda NDA + Rwanda FDA + Nigeria NAFDAC + Ethiopia EFDA harmonised dossier-element reuse alongside national-specific extensions.